July 29, 2016
Recommended Topic Related To:

Nesina

"The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called keto"...

A A A

Nesina




Nesina Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Last reviewed on RxList 10/6/2015

Nesina (alogliptin) is an anti-diabetic drug used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Nesina should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Common side effects of Nesina include cold symptoms (stuffy nose, sore throat, sinus infection, sinus pain), or headache.

The recommended dose of Nesina is 25 mg once daily. Nesina may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before taking Nesina. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Our Nesina (alogliptin) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Nesina in Detail - Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Stop using alogliptin and call your doctor at once if you have:

  • severe pain in your upper stomach spreading to your back;
  • nausea and vomiting, loss of appetite, fast heart rate;
  • itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or
  • severe skin reaction -- fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.

Common side effects may include:

  • headache; or
  • cold symptoms such as stuffy nose, sinus pain, sore throat.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Nesina (Alogliptin Tablets)

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Nesina FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

The following serious adverse reactions are described below or elsewhere in the prescribing information:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

A total of 14,778 patients with type 2 diabetes participated in 14 randomized, double-blind, controlled clinical trials of whom 9052 subjects were treated with NESINA, 3469 subjects were treated with placebo and 2257 were treated with an active comparator. The mean duration of diabetes was seven years, the mean body mass index (BMI) was 31 kg/m² (49% of patients had a BMI ≥ 30 kg/m² ), and the mean age was 58 years (26% of patients ≥ 65 years of age). The mean exposure to NESINA was 49 weeks with 3348 subjects treated for more than one year.

In a pooled analysis of these 14 controlled clinical trials, the overall incidence of adverse reactions was 73% in patients treated with NESINA 25 mg compared to 75% with placebo and 70% with active comparator. Overall discontinuation of therapy due to adverse reactions was 6.8% with NESINA 25 mg compared to 8.4% with placebo or 6.2% with active comparator.

Adverse reactions reported in ≥ 4% of patients treated with NESINA 25 mg and more frequently than in patients who received placebo are summarized in Table 1.

Table 1: Adverse Reactions Reported in ≥ 4% Patients Treated with NESINA 25 mg and More Frequently Than in Patients Given Placebo in Pooled Studies

  Number of Patients (%)
NESINA 25 mg
N=6447
Placebo
N=3469
Active Comparator
N=2257
Nasopharyngitis 309 (4.8) 152 (4.4) 113 (5.0)
Upper Respiratory Tract Infection 287 (4.5) 121 (3.5) 113 (5.0)
Headache 278 (4.3) 101 (2.9) 121 (5.4)

Hypoglycemia

Hypoglycemic events were documented based upon a blood glucose value and/or clinical signs and symptoms of hypoglycemia.

In the monotherapy study, the incidence of hypoglycemia was 1.5% in patients treated with NESINA compared to 1.6% with placebo. The use of NESINA as add-on therapy to glyburide or insulin did not increase the incidence of hypoglycemia compared to placebo. In a monotherapy study comparing NESINA to a sulfonylurea in elderly patients, the incidence of hypoglycemia was 5.4% with NESINA compared to 26% with glipizide (Table 2).

Table 2: Incidence and Rate of Hypoglycemia* in Placebo and Active-Controlled Studies when NESINA Was Used as Add-On Therapy to Glyburide, Insulin, Metformin, Pioglitazone or Compared to Glipizide or Metformin

Add-On to Glyburide (26 Weeks) NESINA 25 mg Placebo
  N=198 N=99
  Overall (%) 19 (9.6) 11 (11.1)
  Severe (%)† 0 1 (1)
Add-On to Insulin (± Metformin) (26 Weeks) NESINA 25 mg Placebo
  N=129 N=129
  Overall (%) 35 (27) 31 (24)
  Severe (%)† 1 (0.8) 2 (1.6)
Add-On to Metformin (26 Weeks) NESINA 25 mg Placebo
  N=207 N=104
  Overall (%)  0 3 (2.9)
  Severe (%/ 0 0
Add-On to Pioglitazone (± Metformin or Sulfonylurea) (26 Weeks) NESINA 25 mg Placebo
  N=199 N=97
  Overall (%) 14 (7.0) 5 (5.2)
  Severe (%)† 0 1 (1)
Compared to Glipizide (52 Weeks) NESINA 25 mg Glipizide
  N=222 N=219
  Overall (%) 12 (5.4) 57 (26)
  Severe (%)† 0 3 (1.4)
Compared to Metformin (26 Weeks) NESINA 25 mg Metformin 500 mg twice daily
  N=112 N=109
  Overall (%) 2 (1.8) 2 (1.8)
  Severe (%)† 0 0
Add-On to Metformin Compared to Glipizide (52 Weeks) NESINA 25 mg Glipizide
  N=877 N=869
  Overall (%) 12 (1.4) 207 (23.8)
  Severe (%)† 0 4 (0.5)
*Adverse reactions of hypoglycemia were based on all reports of symptomatic and asymptomatic hypoglycemia; a concurrent glucose measurement was not required; intent-to-treat population.
† Severe events of hypoglycemia were defined as those events requiring medical assistance or exhibiting depressed level or loss of consciousness or seizure.

In the EXAMINE trial, the incidence of investigator reported hypoglycemia was 6.7% in patients receiving NESINA and 6.5% in patients receiving placebo. Serious adverse reactions of hypoglycemia were reported in 0.8% of patients treated with NESINA and in 0.6% of patients treated with placebo.

Renal Impairment

In glycemic control trials in patients with type 2 diabetes, 3.4% of patients treated with NESINA and 1.3% of patients treated with placebo had renal function adverse reactions. The most commonly reported adverse reactions were renal impairment (0.5% for NESINA and 0.1% for active comparators or placebo), decreased creatinine clearance (1.6% for NESINA and 0.5% for active comparators or placebo) and increased blood creatinine (0.5% for NESINA and 0.3% for active comparators or placebo) [see Use in Specific Populations].

In the EXAMINE trial of high CV risk type 2 diabetes patients, 23% of patients treated with NESINA and 21% of patients treated with placebo had an investigator reported renal impairment adverse reaction. The most commonly reported adverse reactions were renal impairment (7.7% for NESINA and 6.7% for placebo), decreased glomerular filtration rate (4.9% for NESINA and 4.3% for placebo) and decreased renal clearance (2.2% for NESINA and 1.8% for placebo). Laboratory measures of renal function were also assessed. Estimated glomerular filtration rate decreased by 25% or more in 21.1% of patients treated with NESINA and 18.7% of patients treated with placebo. Worsening of chronic kidney disease stage was seen in 16.8% of patients treated with NESINA and in 15.5% of patients treated with placebo.

Postmarketing Experience

The following adverse reactions have been identified during the postmarketing use of NESINA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia, acute pancreatitis, diarrhea, constipation, nausea, and ileus [see WARNINGS AND PRECAUTIONS].

Read the entire FDA prescribing information for Nesina (Alogliptin Tablets)

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.